Integragen (France) Performance
| ALINT Stock | EUR 0.44 0.01 2.22% |
The company retains a Market Volatility (i.e., Beta) of 0.16, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Integragen's returns are expected to increase less than the market. However, during the bear market, the loss of holding Integragen is expected to be smaller as well. At this point, Integragen has a negative expected return of -0.4%. Please make sure to check out Integragen's treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Integragen performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Integragen has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in December 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Integragen |
Integragen Relative Risk vs. Return Landscape
If you would invest 62.00 in Integragen on August 25, 2024 and sell it today you would lose (18.00) from holding Integragen or give up 29.03% of portfolio value over 90 days. Integragen is generating negative expected returns and assumes 5.1214% volatility on return distribution over the 90 days horizon. Simply put, 45% of stocks are less volatile than Integragen, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Integragen Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Integragen's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Integragen, and traders can use it to determine the average amount a Integragen's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0786
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ALINT |
Estimated Market Risk
| 5.12 actual daily | 45 55% of assets are more volatile |
Expected Return
| -0.4 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Integragen is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Integragen by adding Integragen to a well-diversified portfolio.
Integragen Fundamentals Growth
Integragen Stock prices reflect investors' perceptions of the future prospects and financial health of Integragen, and Integragen fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Integragen Stock performance.
| Return On Equity | 0.15 | |||
| Return On Asset | 0.0149 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | 0.02 % | |||
| Current Valuation | 5.39 M | |||
| Shares Outstanding | 6.6 M | |||
| Price To Earning | 44.59 X | |||
| Price To Book | 3.91 X | |||
| Price To Sales | 0.63 X | |||
| Revenue | 11.32 M | |||
| EBITDA | 20.18 K | |||
| Cash And Equivalents | 1.84 M | |||
| Cash Per Share | 0.77 X | |||
| Total Debt | 1.95 M | |||
| Debt To Equity | 0.93 % | |||
| Book Value Per Share | 0.31 X | |||
| Cash Flow From Operations | (2.49 M) | |||
| Earnings Per Share | 0.04 X | |||
| Total Asset | 9.6 M | |||
| Retained Earnings | (39 M) | |||
| Current Asset | 6 M | |||
| Current Liabilities | 4 M | |||
About Integragen Performance
Assessing Integragen's fundamental ratios provides investors with valuable insights into Integragen's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Integragen is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
IntegraGen SA provides human genome analysis services for academic and private laboratories in France and the United States. IntegraGen SA was founded in 2000 and is headquartered in vry, France. INTEGRAGEN operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 43 people.Things to note about Integragen performance evaluation
Checking the ongoing alerts about Integragen for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Integragen help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Integragen generated a negative expected return over the last 90 days | |
| Integragen has high historical volatility and very poor performance | |
| Integragen has some characteristics of a very speculative penny stock | |
| Integragen has accumulated about 1.84 M in cash with (2.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.77, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 66.0% of the company shares are held by company insiders |
- Analyzing Integragen's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Integragen's stock is overvalued or undervalued compared to its peers.
- Examining Integragen's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Integragen's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Integragen's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Integragen's stock. These opinions can provide insight into Integragen's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Integragen Stock Analysis
When running Integragen's price analysis, check to measure Integragen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integragen is operating at the current time. Most of Integragen's value examination focuses on studying past and present price action to predict the probability of Integragen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integragen's price. Additionally, you may evaluate how the addition of Integragen to your portfolios can decrease your overall portfolio volatility.